Claim 1: an Antibody or Antigen binding fragment with (a) binds to an epitope of Human pd-1 recognized by an Antibody which comprises a variable region of light chain is the amino acid sequence of SEQ ID No. 8 and a variable region of heavy chain It has an amino acid sequence of SEQ ID no. 13 or (b) Competes for Binding with Human pd-1An Antibody which comprises a variable region of light chain is the amino acid sequence of SEQ ID No. 8 and a variable region of heavy chain is the amino acid sequence of SEQ ID no. 13.Claim 2: an Antibody or Antigen binding fragment that joins with the PD - 1, where the Antibody or Antigen binding fragment with comprises: (a) a light chain variable region (VL) comprising the complementarity Determining Region 1 VL VL (CDR1), C DR2 and VL CDr3 of any of the Antibodies pd1ab pd1ab - 1, - 2, - 3, - 4 pd1ab, pd1ab,Pd1ab - 5 or 6 pd1ab - as set out in Table 1 and \/ or (b) a variable region of heavy chain (VH) comprising VH complementarity Determining Region 1 (CDR1, CDR2 and CDr3 VH VH) of any of the Antibodies pd1ab pd1ab - 1, - 2, - pd1ab pd1ab 3, - 4, - 5, - 6 pd1ab pd1ab or as required In Table 2.Claim 69: a composition comprising the Antibody or Antigen binding fragment with according to any one of claims 1 - 68 and a pharmaceutically acceptable Carrier. Claim: a 70 polinucle\u00f3tido comprising nucleotide sequences encoding both VH, VL and VH and VL Antibody according to any one of claims 1 - 68.Claim 79: a preparation method of an Antibody or Antigen binding fragment that binds specifically to an epitope of Human pd-1, which includes the polinucle\u00f3tido Express according to claim 70 to 72.Claim 80: a method of Attenuating the activity of a T Cell, comprising contacting the cell with an effective amount of an Antibody or Antigen binding fragment according to any one of claims 1 to 68.Reivindicación 1: Un anticuerpo o su fragmento de unión con el antígeno que (a) se une con un epítope de PD-1 humana reconocido por un anticuerpo
